AbbVie reported mixed fourth-quarter results, with strong growth in immunology and neuroscience drugs countering weakness in its aesthetics portfolio and broader pricing headwinds. While revenue slightly missed estimates, adjusted earnings per share beat expectations.
The pharmaceutical giant AbbVie projects profits exceeding analyst expectations for 2026, buoyed by the stellar performance of its newer immunology drugs Skyrizi and Rinvoq, which are successfully offsetting the decline of its former top-seller Humira.
Pharmaceutical giant Eli Lilly announces a major investment in a new Lehigh Valley manufacturing site, set to create hundreds of jobs and bolster U.S. production capacity for its in-demand injectable therapies, including weight-loss drugs.
Pharmaceutical giant Eli Lilly announces a major $3.5 billion manufacturing expansion for its weight-loss drugs and enters two strategic research collaborations in gene editing and immunology, signaling aggressive growth plans amid a recent stock valuation dip.
Investors face a classic choice between AbbVie's steady dividends and Abivax's high-risk, high-reward potential as both target lucrative immunology markets.
The Danish pharmaceutical giant forecasts a significant drop in revenue for the year, citing fierce competition for its weight-loss drugs and U.S. government pricing initiatives. The projected decline steeper than analyst expectations triggered a sharp sell-off in its U.S.-listed shares.
A provocative analysis suggests the widespread adoption of GLP-1 drugs like Ozempic and Wegovy could trim airline fuel bills by reducing passenger weight, potentially passing savings to travelers. But industry experts debate whether the math adds up.
Eli Lilly's fourth-quarter revenue surged 42.6%, fueled by overwhelming demand for its weight-loss and diabetes treatments. The pharmaceutical giant's robust performance and bullish outlook underscore its dominant position in the fast-growing GLP-1 market.
Sanofi reports a pivotal Phase 3 win for its investigational therapy venglustat in a rare neurological disorder, alongside positive EU regulatory news for Rezurock and progress for amlitelimab, signaling a strategic shift toward high-value specialty medicines.
A new wave of advanced GLP-1 therapies from Eli Lilly, Novo Nordisk, and Amgen, valued at a combined $68 billion, promises to reshape the obesity treatment landscape with improved efficacy and convenience.
Driven by blockbuster sales of its weight-loss and diabetes treatments, Eli Lilly's 2025 revenue surged 45%, with the company forecasting even stronger growth for 2026 as it prepares to launch a pivotal oral therapy.
Novo Nordisk, the Danish pharmaceutical giant behind Ozempic and Wegovy, saw its market value plummet by billions after forecasting a significant sales decline for the year, driven by falling drug prices in its crucial U.S. market.
GSK's annual net profit more than doubled in 2025, fueled by robust sales of HIV, respiratory, and oncology medicines. The results signal a strong recovery for the pharma giant after settling costly U.S. lawsuits related to its discontinued heartburn drug Zantac.
This year's Super Bowl advertising lineup is dominated by wellness themes, but the most consequential push comes from telehealth companies and pharma giants seeking to reshape the narrative around blockbuster GLP-1 medications, moving beyond weight loss to broader health benefits.
As millions tune in for the big game, advertisers are betting millions more on a mix of cutting-edge tech, health trends, and celebrity power to capture viewer attention, making this year's commercial lineup a cultural barometer of its own.
New late-breaking data for Nektar Therapeutics' lead drug candidate, rezpegaldesleukin, suggests systemic anti-inflammatory benefits in patients with comorbid asthma, potentially expanding its market reach and strengthening the investment case for the biopharma firm.
The pharmaceutical giant's final major U.S. facility will rise in Pennsylvania's historic Lehigh Valley, aiming to produce its promising triple-hormone drug retatrutide and bolster domestic supply chains for blockbuster obesity treatments.
With its blockbuster Humira era in the rearview, AbbVie is betting big on its next-generation immunology drugs and a deep pipeline to drive growth and maintain its crown among Dividend Kings.
Pharmaceutical giant Eli Lilly announces a massive $3.5 billion investment in a new Pennsylvania manufacturing facility, aiming to scale up production of its blockbuster weight-loss therapies like retatrutide amid soaring global demand.
Eli Lilly reported a blockbuster 2025 with revenue soaring 45% to $65.2B, fueled by its incretin drugs. Despite anticipating significant pricing headwinds, the company projects 2026 revenue to reach $80-$83B, banking on volume growth from new launches and an expanding late-stage portfolio.
